Shots:

• GenEdit to receive ~$57M up front and is also eligible to receive future development, regulatory and commercial milestones along with royalties. Sarepta gets exclusive option rights to license polymer nanoparticles that were developed by GenEdit for 4 neuromuscular indications
• The collaboration will combine Sarepta’s gene-editing technologies and GenEdit’s non-viral delivery platform to develop new genetic therapies for patients with neuromuscular diseases
• Additionally, in vivo results showed the potential of GenEdit’s polymer nanoparticles to deliver therapeutic cargo at muscle tissue after systemic administration to target & non-viral systemic delivery of genetic medicines

Ref: Globe Newswire | Image: Fierce Biotech